Chester County News and Community Website
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with moderately …
Johnson & Johnson’s TREMFYA® Shows Promising Results in Ulcerative Colitis Patients Read More
EXTON, PA — Lungpacer Medical has unveiled promising results from its groundbreaking STIMULUS trial, a Phase 1 study conducted in collaboration with Toronto General Hospital. Presented at the 2025 Transcatheter Heart …
Lungpacer Medical Shares Promising Results from STIMULUS Trial Read More
MALVERN, PA — YPrime has introduced groundbreaking updates to its electronic clinical outcome assessment (eCOA) platform, announcing a new AI Migration Tool designed to transform the way clinical trials are conducted …
YPrime Unveils AI-Powered Innovations to Revolutionize Global Clinical Trials Read More
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development program at major scientific conferences, presenting data on the first 10 patients treated …
Cabaletta Bio Reveals Promising Clinical Data for Autoimmune Therapy Read More SPRING HOUSE, PA — Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent publication in mAbs. The study showcases the drug’s high-affinity binding capabilities …
Johnson & Johnson Highlights Promising Data on Investigational Autoantibody Drug Nipocalimab Read More
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has unveiled promising peer-reviewed results from its Phase 1/2 clinical trial for INO-3107, a cutting-edge DNA medicine designed to treat recurrent respiratory papillomatosis (RRP). …
INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) revealed promising new findings on its atrioventricular interval modulation (AVIM) therapy during a late-breaking presentation at the Technology and Heart Failure …
Orchestra BioMed Unveils Groundbreaking Data on AVIM Therapy’s Potential to Prevent Heart Failure Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) showcased encouraging results from the Phase 2b SEISMiC study of istaroxime, its novel investigational therapy for early cardiogenic shock, at the Technology and …
Windtree Therapeutics Highlights Promising Phase 2b Results for Istaroxime Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for OCU410. This novel multifunctional modifier gene therapy …
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved! Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported its financial results for the fourth quarter and full year ending December 31, 2024, while sharing significant updates on the development of …
Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for Lorundrostat Read More